The group's principal activity is to develop and market pharmaceutical products for the treatment of metabolic, hormone growth disorders, diabetes and endocrine disorders. The group has two drug candidates, recombinant human insulin-like growth factor-i bound to recombinant human insulin-like growth factor binding protein-3 (rhigf-i) also known as somatokine and rhigfbp-3. These drugs are developed to treat indications in the metabolic and oncology fields. Also correct metabolic defects in the human body by replacing key regulatory molecules in a physiologically relevant fashion.
